Regeneron Pharmaceuticals has emerged as one of the most prolific wellsprings of new antibody drugs in the biopharma universe thanks to its success in combining innovative technologies with intelligent target selection. With three drugs on the market and a landmark partnership with Sanofi providing up to $160 million in annual research funding through at least 2017, Regeneron appears to have laid the foundation to potentially vie for a place among the biggest biotechs in the world. The company’s pipeline was once again in the spotlight last week when positive data were presented for dupilumab for moderate-to-severe atopic dermatitis.
Hey, check out all the research scientist jobs. Post your resume today!
